Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | IL1RN | P18510 | 1/20 | 0.50 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.50 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.50 |
| ▸ | CTSB | P07858 | 4/20 | 0.48 |
| ▸ | CTSK | P43235 | 2/20 | 0.48 |
| ▸ | CTSL | P07711 | 2/20 | 0.47 |
| ▸ | CTSS | P25774 | 2/20 | 0.47 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.47 |
| ▸ | ELANE | P08246 | 2/20 | 0.45 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22004939 | 1.00 | ALDH1A1 (0.50) | ALDH1A1IL1RNERAP2ERAP1CTSB | |
| SCHEMBL2138849 | 1.00 | ALDH1A1 (0.50) | ALDH1A1IL1RNERAP2ERAP1CTSB | |
| Hydrochloric Acid SCHEMBL2136937 | 0.98 | IL1RN (0.49) | ALDH1A1IL1RNERAP2ERAP1CTSB | |
| Hydrochloric Acid SCHEMBL2136927 | 0.98 | IL1RN (0.49) | ALDH1A1IL1RNERAP2ERAP1CTSB | |
| Hydrochloric Acid SCHEMBL2138843 | 0.98 | IL1RN (0.49) | ALDH1A1IL1RNERAP2ERAP1CTSB | |
| SCHEMBL22346392 | 0.88 | CTSL (0.55) | ALDH1A1CTSBCTSKCTSLCTSS | |
| SCHEMBL22346390 | 0.88 | CTSL (0.55) | ALDH1A1CTSBCTSKCTSLCTSS | |
| SCHEMBL21959513 | 0.84 | PPID (0.50) | ALDH1A1IL1RNERAP2ERAP1CTSB | |
| SCHEMBL6831165 | 0.84 | ALDH1A1 (0.47) | ALDH1A1IL1RNERAP2ERAP1 | |
| SCHEMBL21959514 | 0.84 | PPID (0.50) | ALDH1A1IL1RNERAP2ERAP1CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2447265-A1 | NOVEL THIOPHENE CARBOXAMIDE DERIVATIVE AND MEDICINAL USE OF SAME | Sanwa Kagaku Kenkyusho Co., Ltd (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-20120101137-A1 | NOVEL THIOPHENECARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101137-A1 | NOVEL THIOPHENECARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | GCK, GCKR, HK2 | ALDH1A1 2623/4885IL1RN 3174/4885ERAP2 1175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.